

November 7, 2019



## Aptose to Present at BIO-Europe Conference

SAN DIEGO and TORONTO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate in the 25<sup>th</sup> Annual International BIO-Europe Partnering Conference, being held November 11<sup>th</sup> -13<sup>th</sup> in Hamburg, Germany. Aptose will be presenting and hosting 1x1 meetings.

### 25<sup>th</sup> Annual International BIO-Europe Partnering Conference

Presentation Tuesday, November 12, 2019, 15:45

Date: CET

Location: Hamburg Messe, Hamburg  
Level 0, B1, Room 4

### About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies: CG-806, an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1 trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies; APTO-253, the only clinical stage agent that directly targets the MYC oncogene and inhibits its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS). For further information, please visit [www.apdose.com](http://www.apdose.com).

For further information, please contact:

#### Aptose Biosciences

Greg Chow  
Senior Vice President, CFO  
650-718-5028  
[gchow@aptose.com](mailto:gchow@aptose.com)

#### SMP Communications

Susan Pietropaolo  
201-923-2049  
[susan@smpcommunications.com](mailto:susan@smpcommunications.com)

#### LifeSci Advisors, LLC

Daniel Ferry  
Managing Director  
617-535-7746  
[Daniel@lifesciadvisors.com](mailto:Daniel@lifesciadvisors.com)



Source: Aptose Biosciences, Inc.